These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24971446)

  • 1. Elimination on the agenda for hepatitis C.
    Burki T
    Lancet Infect Dis; 2014 Jun; 14(6):452-3. PubMed ID: 24971446
    [No Abstract]   [Full Text] [Related]  

  • 2. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.
    Phelan M; Cook C
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S5. PubMed ID: 25253373
    [No Abstract]   [Full Text] [Related]  

  • 3. Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
    Price JC; Terrault NA
    Liver Int; 2015 Jan; 35(1):7-8. PubMed ID: 25183500
    [No Abstract]   [Full Text] [Related]  

  • 4. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
    Einecke D
    MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
    [No Abstract]   [Full Text] [Related]  

  • 5. The price of good health.
    Nat Med; 2014 Apr; 20(4):319. PubMed ID: 24710362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant Ninja viruses.
    Foster GR
    Hepatology; 2015 Feb; 61(2):421-3. PubMed ID: 25266372
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicine. Hepatitis C can be cured globally, but at what cost?
    Hill A; Cooke G
    Science; 2014 Jul; 345(6193):141-2. PubMed ID: 25013048
    [No Abstract]   [Full Text] [Related]  

  • 8. Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection.
    Saag MS
    JAMA; 2014 Jul 23-30; 312(4):347-8. PubMed ID: 25038351
    [No Abstract]   [Full Text] [Related]  

  • 9. Guideline: New HCV drugs should go to sickest patients.
    Kuehn BM
    JAMA; 2014 Sep; 312(11):1084-5. PubMed ID: 25226461
    [No Abstract]   [Full Text] [Related]  

  • 10. China rejects patent on hepatitis C drug sofosbuvir.
    Kmietowicz Z
    BMJ; 2015 Jun; 350():h3429. PubMed ID: 26105994
    [No Abstract]   [Full Text] [Related]  

  • 11. [Is more expensive always better?].
    Drenth JP
    Ned Tijdschr Geneeskd; 2014; 159():A8556. PubMed ID: 25534272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better.
    Aghemo A; Donato MF
    Gastroenterology; 2015 Jan; 148(1):13-6. PubMed ID: 25451651
    [No Abstract]   [Full Text] [Related]  

  • 13. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment.
    Sultanik P; Klotz C; Brault P; Pol S; Mallet V
    Blood; 2015 Apr; 125(15):2446-7. PubMed ID: 25858892
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening urged for hepatitis C but drug costs are prohibitive.
    Fralick M
    CMAJ; 2014 Mar; 186(5):329. PubMed ID: 24549123
    [No Abstract]   [Full Text] [Related]  

  • 16. WHO issues guidelines on HCV amid drug cost controversy.
    Slomski A
    JAMA; 2014 Jun; 311(22):2262-3. PubMed ID: 24915242
    [No Abstract]   [Full Text] [Related]  

  • 17. Interferon free hepatitis C treatment regimens: the beginning of another era.
    Poordad F; Chee GM
    Curr Gastroenterol Rep; 2012 Feb; 14(1):74-7. PubMed ID: 22105465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir approved for chronic hepatitis C infection.
    Traynor K
    Am J Health Syst Pharm; 2014 Jan; 71(2):90. PubMed ID: 24375596
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
    Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.